Literature DB >> 33818295

Prognostic value of peripheral blood CD14+HLA-DR+ monocytes in patients with acute pancreatitis.

Georgi Minkov1, Evgeni Dimitrov1, Yovcho Yovtchev1, Emil Enchev1, Rumyana Lokova2, Krasimira Halacheva2.   

Abstract

Acute pancreatitis (AP) is characterized by a potent pro-inflammatory response and concomitant anti-inflammatory response leading to a state of immunosuppression. Decreased HLA (Human Leukocyte Antigen)-DR expression on monocytes is a reliable cellular marker of immune suppression. The main objective of this study was to investigate the clinical value of the percentage of peripheral blood CD14+ HLA-DR+ monocytes (mHLA-DR) for diagnosis and assessment of severity, development of organ failures (OF), local complications (LC), and infected necrosis (IN), and outcome in patients with AP. Flow cytometry was used to measure the percentage of peripheral blood mHLA-DR at different time points in 82 patients with AP enrolled during the period of 2012-2018 admitted to University Hospital Stara Zagora, Bulgaria. The percentages of peripheral blood mHLA-DR in AP patients were significantly associated with severity, development of LC, OF, IN (measured at admission, on the 48th hour and on the 5th day) and with outcome (measured on the 5th day) of AP. The value of peripheral blood mHLA-DR may be used as a biological marker in the diagnosis and assessment of severity, development of OF, LC, IN and to predict outcome in AP.

Entities:  

Keywords:  Acute pancreatitis; flow cytometry; human leukocyte antigen-dr (hla-dr); immunosuppression

Mesh:

Substances:

Year:  2021        PMID: 33818295     DOI: 10.1080/15321819.2021.1903491

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN: 1532-1819


  1 in total

1.  Immune Dysfunction is Associated with Readmission in Survivors of Sepsis Following Infected Pancreatic Necrosis.

Authors:  Jiangtao Yin; Wenjian Mao; Xiaojia Xiao; Xianqiang Yu; Baiqiang Li; Faxi Chen; Jiajia Lin; Jing Zhou; Jing Zhou; Zhihui Tong; Lu Ke; Weiqin Li
Journal:  J Inflamm Res       Date:  2021-10-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.